Objective:

To determine relationship between clinical characteristics, laboratory results and treatments with 12 month mortality in COVID-19.

Materials and methods:

A retrospective cohort study was conducted in three hospitals in Colombia. Odds ratios (OR) were calculated using multivariate logistic regression analysis with outcome variable mortality at 12 months.

Results:

A total of 1194 patients were included out of 4344 potential eligible subjects, average age was 57.7 years. The group of patients who died at 12 months showed a lymphocyte count of 922.6 (SD:572.32) compared to 1200.1 (SD:749.45) in the group of survivors (p 0.001). Hemoglobin averaged 2.1 g/dl less in the patients who died compared to the control group (14.5 vs. 12.4; p0.001). The blood urea nitrogen (33.3 vs. 19.3; p 0.001) was higher in patients who died at 12-month follow-up compared to the surviving group. Age70 years OR:7.2 (95%CI:3.9-13.3) and adjusted OR:1.05 (95%CI:1.01-1.08) (p=0.023), Charlson index 4 OR:7.8 (95%CI:4.3-14.1) and adjusted OR:1.35 (95%CI:1.1-1.67) (p=0.005), dexamethasone OR:0.3 (95%CI:0.2-0.6) and adjusted OR:0.3 (95%CI:0.14-0.65) (p=0.002) and pronation OR:0.3 (95%CI:0.1-1) and adjusted OR:0.4 (95%CI:0.08-1.87) (p=0.242).

Conclusions:

The increased risk of death 12 months after acute SARS-CoV-2 infection is associated with clinical variables such as age 70 years and Charlson index 4. Use of prone ventilation and dexamethasone were associated with increased survival.

        · abstract in Spanish     · text in English     · English ( pdf )